Hamid Mirshahidi, MD Associate Professor, Medicine School of Medicine

Research & Grantsmanship 

  Funded Research Project (PI)

• A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed By Q 2 Week Doxorubicin (A) and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) As Neoadjuvant Therapy for Inflammatory and Locally Advanced Her-2/Neu Negative Breast Cancer ( 12/2010 - 10/2012 )

• Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without BSI-201 (SAR240550) (a PARP1 Inhibitor) in Subjects with Previously Untreated Stage IV Squamous Non Small-Cell Lung Cancer (NSCLC) ( 6/2010 - 5/2012 )

• A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment ( 4/2008 - 3/2012 )

• A Randomized Phase III Trial of weekly Paclitaxel compared to weekly Nanoparticle Albumin Bound NAB-Paclitaxel or Ixabepione combined with or without Bevacizumab as first-line therapy for Locally Recurrent or Metastatic Breast Cancer ( 3/2010 - 11/2011 )

• Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study ( 6/2008 - 6/2011 )

• Research project on cell signaling and role of over-expressed RhoC-GTPase in inflammatory breast cancer, Department of Hematology / Oncology, University of Michigan, Ann Arbor, MI.  Aug-Sept, 2000 (Laboratory Experience). ( 8/2000 - 9/2000 )

• Clinical study on the role of Angiotensin Receptor Blockers in prevention of renal failure in patients with Diabetes, Sansum Medical Research Institute, Santa Barbara, CA.  March – November 1998. ( 3/1998 - 11/1998 )

• Research project on the role of lipoproteins in patients with atherosclerosis, UCLA, Department of Cardiology, Atherosclerosis Research Unit, Los Angeles, CA.  May – July 1998. ( 5/1998 - 7/1998 )

• A Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy-EGFRI 18 (FACT-EGFRI 18) Questionnaire for EGFR-Induced Skin Toxicities ( 2/2012 - Present )

• A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less ( 4/2011 - Present )

• A Phase 1-2 trial of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer ( 1/2011 - Present )

• A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer ( 1/2011 - Present )

• Phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus ( 12/2010 - Present )

• A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy. ( 3/2010 - Present )

• A Phase I/II Clinical Trial of Bortezomib (Velcade) + Pemetrexed (Alimta) in PreviouShan Limy Treated Patients with Advanced Non-Small Cell Lung Cancer ( 8/2008 - Present )